Kawasaki disease is an acute, febrile vasculitis that primarily affects children under the age of five and ranks among the most common causes of acquired heart disease in children worldwide. Its classical presentation includes prolonged fever together with a constellation of mucocutaneous findings: bilateral conjunctival injection, changes of the lips and oral cavity, a polymorphous rash, swelling of the hands and feet, and cervical lymphadenopathy. Yet a substantial proportion of children never display the full set of features. These patients are classified as having incomplete Kawasaki disease, a diagnostic challenge because the stakes are high. Without timely treatment with intravenous immunoglobulin and aspirin, the coronary arteries can become inflamed and dilate, laying the groundwork for aneurysms and long-term cardiovascular complications. Laboratory markers such as elevated inflammatory indices, leukocytosis, thrombocytosis, anaemia and hypoalbuminaemia, together with echocardiographic findings, often tip the balance toward treatment in ambiguous cases.

That is precisely the path taken with the young patient at the centre of this report. At 18 months of age she presented with persistent fever and enlarged cervical lymph nodes, but without the other classical mucocutaneous features that would have made the diagnosis straightforward. Her laboratory results were striking: markedly elevated inflammatory markers, leukocytosis, thrombocytosis, anaemia and low albumin levels. Echocardiography added a decisive piece of evidence, revealing dilatation of the left anterior descending coronary artery and a mild pericardial effusion. Taken together, these findings satisfied the criteria for incomplete Kawasaki disease, and she was treated with intravenous immunoglobulin and aspirin. Her response was favourable, and follow-up imaging showed that the coronary artery abnormalities normalised, an outcome that underscores how effective standard therapy can be even when the underlying biology of the illness remains obscure.

The story might have ended there, a single episode of vasculitis successfully treated. Instead, the following two years brought a pattern that could no longer be dismissed as bad luck. The girl developed recurrent respiratory infections, suffered an episode of Salmonella gastroenteritis, and the lymphadenopathy in her neck refused to resolve. Persistent lymph node enlargement is a recognised hallmark of AICDA deficiency, in which the immune system’s failure to mature antibodies properly leads to prominent lymphoid hyperplasia. But at the time, the treating team faced a child whose infection history was worrying rather than diagnostic. It was this accumulation of recurrent bacterial infections, stubborn lymphadenopathy and unexplained susceptibility to organisms such as Salmonella that prompted a formal immunological work-up, the kind of evaluation the authors argue should be triggered earlier when such a triad appears.

The results of that work-up painted a coherent picture of a class-switch recombination defect. Immunological testing demonstrated elevated IgM alongside low levels of IgG and IgA, the signature immunoglobulin profile of hyper-IgM syndromes. Her ability to mount antigen-specific antibody responses after vaccination was impaired, and flow cytometry revealed an absence of switched memory B cells, the population of lymphocytes that has undergone the genetic rearrangement needed to produce IgG, IgA and IgE antibodies. Genetic testing then identified compound heterozygous pathogenic variants in the AICDA gene, confirming autosomal recessive AICDA deficiency, historically termed hyper-IgM syndrome type 2. With the diagnosis in hand, her management shifted to immunoglobulin replacement therapy and antimicrobial prophylaxis, to which she responded well, providing her immune system with the protective antibodies it cannot manufacture on its own.

To appreciate why this diagnosis matters, it helps to understand the molecular machinery involved. Activation-induced cytidine deaminase, the enzyme encoded by AICDA, is expressed in activated B cells within germinal centres of lymphoid tissue. Its job is to initiate both class-switch recombination, the process by which a B cell changes the constant region of its antibody from IgM to IgG, IgA or IgE, and somatic hypermutation, which fine-tunes antibody affinity for its target. When biallelic pathogenic variants disable the enzyme, B cells remain stuck producing IgM, the antibody class that dominates early immune responses but lacks the tissue penetration, complement activation profile and memory characteristics of the switched classes. The consequences are recurrent infections with encapsulated and enteric bacteria, poor vaccine responses, and, as in this patient, enlarged lymph nodes driven by hyperplastic germinal centres that churn out unswitched B cells in a futile attempt to respond.

What makes the case scientifically provocative is the temporal relationship between the Kawasaki disease episode and the later recognition of the immune defect. The authors are careful to state that a causal relationship cannot be established from a single case. Kawasaki disease itself is thought to arise in genetically susceptible children following exposure to environmental triggers, possibly infectious, that set off a hyperinflammatory cascade affecting medium-sized arteries. AICDA deficiency, for its part, is increasingly recognised to involve immune dysregulation beyond simple antibody failure. The possibility raised by this report is that the immune dysregulation associated with AICDA deficiency may contribute to susceptibility to hyperinflammatory vasculitis of the Kawasaki type. If that hypothesis holds up in larger cohorts, it would suggest that some children diagnosed with Kawasaki disease, particularly those with atypical or recurrent features, may carry an underlying inborn error of immunity that shapes their inflammatory response.

The practical message for clinicians is embedded in the case’s chronology. The combination of recurrent bacterial infections, persistent lymphadenopathy and a hyper-IgM immunoglobulin profile should raise suspicion of AICDA deficiency and prompt timely immunological evaluation, including assessment of switched memory B cells and, where indicated, genetic testing. Early diagnosis changes the trajectory of the disease. Immunoglobulin replacement replenishes missing antibody classes, prophylactic antimicrobials reduce the burden of breakthrough infections, and families receive genetic counselling appropriate to an autosomal recessive condition. Conversely, a delayed diagnosis leaves children exposed to repeated infections, unnecessary courses of empiric treatment and the risk of chronic organ damage. The authors also note that the diagnostic criteria for incomplete Kawasaki disease, which lean heavily on laboratory markers and echocardiography, functioned well in this patient, but they could not by themselves reveal the deeper immunological story unfolding beneath the vasculitis.

For the research community, the case adds a new entry to the growing catalogue of immune dysregulation phenomena associated with inborn errors of immunity. Over the past two decades, the boundaries between classical immunodeficiency and autoinflammatory or autoimmune disease have blurred considerably, as genes once thought to govern only one aspect of immunity turn out to have pleiotropic effects. AICDA deficiency presenting with a Kawasaki-like vasculitis fits this pattern, hinting that defective antibody maturation may alter the way the innate immune system responds to common triggers, tilting the balance toward excessive inflammation in the vessel wall. Testing that idea will require systematic collection of vasculitis cases in patients with class-switch defects, and of immune evaluations in children with severe or atypical Kawasaki disease, work that single case reports like this one help to catalyse.

In the meantime, the girl at the centre of the report is doing well on replacement therapy and prophylaxis, her coronary arteries having recovered fully from the episode that first brought her to medical attention. Her case stands as a reminder that a diagnosis, however confident, is sometimes only the first layer of the truth. A fever and swollen lymph nodes in a toddler can signal a familiar vasculitis, a hidden genetic defect, or both in sequence. Paediatricians who hold both possibilities in mind, and who pursue immunological evaluation when infections recur and lymph nodes persist, stand the best chance of finding the deeper answer before the complications find the patient.

Subject of Research: AICDA deficiency presenting as incomplete Kawasaki disease in a paediatric patient

Article Title: Incomplete Kawasaki disease preceding the diagnosis of AICDA deficiency (hyper-IgM syndrome type 2)

Article References: Nashrudin, K. N. M., Bukhari, N. H., Jamaluddin, J., Latiff, A. H. A., Sham, M. M., Siniah, S., Abidin, M. A. Z., & Ismail, I. H. (2026). Incomplete Kawasaki disease preceding the diagnosis of AICDA deficiency (hyper-IgM syndrome type 2). BMC Pediatrics. https://doi.org/10.1186/s12887-026-07847-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07847-7

Keywords: AICDA deficiency, hyper-IgM syndrome type 2, Kawasaki disease, inborn error of immunity, class-switch recombination, lymphadenopathy, paediatric immunology, coronary artery dilatation, immunoglobulin replacement, switched memory B cells, vasculitis, case report

The finding is significant because IgE sits at the very center of the allergic cascade. Allergen-specific IgE is produced exclusively by B cells, and upon re-exposure to an allergen such as house dust mite, these antibodies arm mast cells and basophils, triggering their degranulation and the clinical symptoms of asthma. At the same time, T helper 2 cells recruited to the airways secrete IL-4, IL-5 and IL-13, cytokines that promote local IgE production, eosinophil accumulation, airway hyperresponsiveness and mucus hypersecretion. While the extracellular signals that push B cells toward IgE have been studied extensively, the intrinsic molecular machinery inside B cells that governs this process has remained poorly defined, which is precisely the gap the new work addresses.

The researchers began by asking whether Ssu72 responds to the signals that activate B cells during allergic reactions. In cultured mouse B cells, Ssu72 protein and mRNA levels rose markedly after stimulation with anti-CD40, an antibody that mimics the T cell help B cells receive through CD40 ligation, as well as after combined anti-IgM and anti-CD40 stimulation and exposure to the T helper 2 cytokine IL-4. Crucially, the pattern held in vivo: in a low-dose house dust mite model of allergic asthma, B cells from the spleens of asthmatic mice showed significantly elevated Ssu72 compared with controls, and immunofluorescence imaging revealed heightened Ssu72 expression in B220-positive B cells infiltrating the inflamed lungs. The enzyme, in other words, is switched on exactly where and when the allergic response is being built.

To test whether this upregulation matters functionally, the team generated mice lacking Ssu72 only in B cells by crossing Ssu72-floxed animals with CD19-Cre mice, producing what they call Ssu72-BKO mice. Importantly, baseline B cell development appeared largely intact: total splenic B cell numbers were comparable to wild-type littermates, and with careful gating the major follicular, transitional and marginal zone subsets were unchanged. The knockout mice also mounted normal antigen-specific IgM and IgG responses after immunization with T cell-dependent and T cell-independent antigens, formed normal germinal centers and generated normal plasma cell populations. Ssu72, it seems, is dispensable for general antibody immunity but becomes critical in the specific context of allergic, T helper 2-driven inflammation.

That context-dependence showed itself clearly in the asthma model. After sensitization and challenge with house dust mite extract, Ssu72-BKO mice had visibly less peribronchial and perivascular inflammation on histology, lower inflammation scores, and significantly fewer total cells, eosinophils, T cells and B cells in bronchoalveolar lavage fluid. Immunohistochemistry for B220 and eosinophil cationic protein confirmed reduced B cell and eosinophil infiltration in lung tissue. Most strikingly, serum levels of total and house dust mite-specific IgE and IgG1 were substantially lower in the knockout animals, while HDM-specific IgM, IgG2b and IgG3 were unaffected, indicating that B cell Ssu72 preferentially supports the IgG1 and IgE arms of the allergic antibody response.

Flow cytometry of the mediastinal lymph nodes revealed why. Class switching to IgG1 and IgE normally occurs in germinal centers with help from T follicular helper cells, and in Ssu72-BKO mice both the percentage and number of IgG1-positive B cells, germinal center B cells and T follicular helper cells were significantly reduced after asthma induction. The defect was also cell-intrinsic: when purified B cells from knockout and wild-type mice were stimulated in vitro with LPS plus IL-4, the Ssu72-deficient cells showed markedly fewer IgG1-positive cells at days three and six, fewer intracellular IgE-positive cells at day six, and lower secreted IgG1 and IgE, while IgM production was unaffected. The knockout B cells also proliferated less, expressed less Ki67, survived less well by Annexin V and propidium iodide staining, and showed blunted early activation markers CD69 and CD86.

The study also uncovered a second, mechanistically distinct route by which Ssu72 shapes IgE: the regulation of CD23, the low-affinity IgE receptor. Membrane-bound CD23 on B cells normally restrains IgE synthesis, whereas its cleaved soluble form, sCD23, enhances it. Ssu72-BKO mice produced significantly less sCD23 during house dust mite asthma while retaining higher levels of membrane CD23 on their lymph node B cells. The team traced this to reduced induction of ADAM10, the established sheddase that clips CD23 from the cell surface, and reduced expression of MMP9, a matrix metalloproteinase previously implicated in LPS-driven CD23 cleavage. Consistent with a conserved mechanism, an analysis of public RNA sequencing data from activated human B cells revealed a positive correlation between Ssu72 and MMP9 expression, suggesting the pathway may operate in human allergy as well.

Delving deeper into signaling, the researchers found that Ssu72-deficient B cells had reduced phosphorylation of S6K and S6, canonical readouts of mTORC1 activity, alongside sharply increased phosphorylation of AMPKα at Thr172, the activating modification of the cellular energy sensor AMPK. Because AMPK negatively regulates mTORC1, and mTORC1 drives the protein synthesis and anabolic growth that class-switched B cells need to proliferate and secrete antibody, this imbalance offers a coherent explanation for the defective IgG1 and IgE responses. Co-immunoprecipitation experiments in transfected HEK293T cells and in the human Ramos B cell line demonstrated a physical interaction between Ssu72 and AMPKα, raising the possibility that Ssu72 directly dephosphorylates AMPKα, although the authors note that direct phosphatase assays and catalytically inactive Ssu72 mutants will be needed to confirm AMPKα as a true substrate.

Perhaps the most clinically suggestive result came from adoptive transfer experiments. When B cells from wild-type or Ssu72-deficient donors were transferred into B cell-deficient μMT mice that had already been sensitized to house dust mite, and the recipients were then challenged, the mice receiving Ssu72-deficient B cells developed less lung inflammation, fewer airway eosinophils, T cells and B cells, and lower serum IgE. This shows that Ssu72 matters not only during the sensitization phase, when IgE-switched B cells are generated, but also during the effector phase, when re-exposure to allergen triggers disease. The knockout B cells additionally displayed reduced MHC class II upregulation in lymph nodes and lungs, and the mice showed fewer IL-4- and IL-13-producing CD4-positive T cells in both compartments, along with lower IL-4 in bronchoalveolar lavage fluid and serum, implying that Ssu72-expressing B cells help sustain the T helper 2 dialogue through antigen presentation.

Taken together, the study positions Ssu72 as a context-dependent, B cell-intrinsic checkpoint that licenses class switching to IgG1 and IgE, promotes CD23 shedding through ADAM10 and MMP9, and tunes the AMPK-mTORC1 metabolic axis. Because general humoral immunity was preserved in the knockout mice, the authors argue that selectively targeting Ssu72 in B cells could dampen allergic airway inflammation without broadly compromising the antibody defenses a patient needs against infection. Much remains to be worked out, including how Ssu72 controls ADAM10 and MMP9 expression and how the AMPK and CD23-shedding pathways intersect. But for a disease in which IgE remains a prime therapeutic target, an intracellular enzyme that quietly orchestrates its production offers an enticing new lead, and one that the field will now be eager to pursue from mouse airways toward human clinics.

Subject of Research: The role of the B cell-intrinsic phosphatase Ssu72 in regulating IgE production and allergic airway inflammation

Article Title: B cell-intrinsic Ssu72 phosphatase is a key regulator of allergic asthma

Article References: Koo, S.-Y., Wang, N., Kim, M.-H., Lee, S., Kim, T. J., & Lee, C.-W. (2026). B cell-intrinsic Ssu72 phosphatase is a key regulator of allergic asthma. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01859-0

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01859-0

Keywords: Ssu72 phosphatase, B cells, allergic asthma, IgE, class switch recombination, CD23 shedding, ADAM10, MMP9, AMPK, mTORC1, T helper 2 cytokines, house dust mite

The research team, led by scientists at Human Technopole in Milan, purified naive B cells, which have never encountered an antigen, and unswitched memory B cells, which carry the imprint of past infections, from the blood of healthy donors. They then activated both cell types in the laboratory using a cocktail that mimics T-cell-dependent stimulation: a cross-linker that engages the B cell receptor, multimeric CD40L to trigger the costimulatory CD40 receptor, and the cytokines IL-2 and IL-21. Over six days of culture, the researchers captured single-cell RNA sequencing and B cell receptor sequencing at four time points, from the resting state through the first cell division to full differentiation, retaining nearly 119,000 cells for analysis.

The first surprise came from comparing the two cell types at rest. At day zero, naive and memory B cells showed highly similar gene regulatory network activity, with a correlation of 0.89 across transcription factor regulons. Yet as activation progressed, the two populations drifted apart, and by day six the correlation had fallen to just 0.4. The transcriptional response to the very same stimulus was therefore profoundly cell-type-specific, with more than 3,000 genes differentially expressed between the two populations at the final time point.

That divergence translated into radically different fates. Memory B cells, when activated, almost exclusively differentiated into plasmablasts and plasma cells, the antibody factories of the immune system. Their gene expression was dominated by signatures of endoplasmic reticulum stress and the unfolded protein response, pathways such as IRE1α activating chaperones and XBP1(S) activating chaperone genes, which are hallmarks of cells ramping up massive antibody production. Naive B cells, by contrast, bifurcated. One branch produced plasma cells indistinguishable from those generated by memory cells, while the other adopted a germinal center phenotype marked by high expression of BCL6, CD81 and LIMK1, together with markers of memory precursors such as CCR6 and HHEX. An independent computational approach based on optimal transport, called Moscot, confirmed that germinal center cells arose almost exclusively from proliferating naive B cells, whereas plasmablasts could originate from either population.

The engine behind this fork in the road proved to be a pair of antagonistic transcription factors. The researchers applied the SCENIC framework to infer the activity of gene regulatory networks, or regulons, across the time course. They found that the activity of IRF4, the master driver of plasma cell differentiation, rose steadily in memory B cells from the earliest hours of activation and continued climbing throughout, culminating in expression of its downstream effector PRDM1. In naive B cells, IRF4 activity showed only a transient early increase before declining, persisting at high levels solely in the subset of cells that ultimately committed to the plasma cell fate. The activity of SPI1, also known as PU.1, behaved in exactly the opposite manner: strongly suppressed in memory cells, it rebounded in naive cells and peaked by day six, characterizing the germinal center state. Imaging flow cytometry revealed a mutually exclusive pattern of nuclear localization, with cells showing nuclear IRF4 consistently negative for nuclear PU.1 and vice versa, underscoring the antagonism between the two programs.

To test causality, the team deployed CRISPR-Cas9 to knock out IRF4 and PRDM1 in activated B cells, achieving knockout efficiencies of roughly 98 and 90 percent respectively. The consequences were dramatic. Loss of IRF4 blocked plasma cell differentiation in both naive and memory B cells and pushed the cells toward an aberrant germinal-center-like state that expressed canonical GC markers but differed transcriptionally from naturally arising germinal center cells by more than 2,600 genes. Knockout of PRDM1, in contrast, selectively eliminated plasma cells while preserving the capacity to form germinal center cells that were transcriptionally indistinguishable from those arising in control cultures. The conclusion is that PRDM1 is essential only for the plasma cell program, whereas IRF4 plays a dual and indispensable role, coordinating both plasma cell differentiation and proper germinal center development.

Perhaps the most conceptually striking finding concerns clonal behavior. By culturing only about 2,000 naive B cells and sequencing the entire culture at day six, the researchers identified 265 clones with at least ten cells each. A large proportion of these clones contained both plasma cells and germinal center cells, demonstrating that a single ancestral B cell can give rise to both fates. This rules out a simple population-level model in which different cells are pre-committed to different outcomes, and instead points to stochastic fluctuations in IRF4 expression within individual cells as the source of the bifurcation, particularly because the polyclonal stimulation system excludes any selection by antigen affinity.

The clonal analysis also revealed that gene expression itself is heritable. Sister cells within a clone showed significantly correlated expression of key plasma cell genes, including XBP1 and the immunoglobulin heavy chain gene IGHM, whereas random cell pairs from the same donor showed no such correlation. Genes regulated by XBP1 displayed especially strong intraclonal correlation, indicating that transcriptional programs central to the plasma cell lineage are inherited across cell divisions. To quantify this, the researchers trained three machine learning classifiers, logistic regression, a neural network and a random forest, to predict clonal identity from gene expression alone. Using a set of 369 genes with clonal correlation above 0.25, the logistic regression model correctly assigned sister cells with an average accuracy of nearly 88 percent, and the performance held up even after cell cycle and cell state effects were regressed out. Validation on eleven independent in vivo mouse B cell clonal datasets confirmed that the phenomenon is not an artifact of the culture system.

The study also shed light on antibody class switching, the process by which B cells replace the constant region of their antibody heavy chain to produce IgG, IgA or IgE while retaining antigen specificity. Using the sciCSR pipeline to quantify germline transcripts, the short non-coding RNAs that mark switch regions poised for recombination, the researchers found that more than 75 percent of germinal center cells expressed germline IGHG3, compared with only about 25 percent of plasma cells. Yet this priming did not translate into more switching, confirming that germline transcription is necessary but not sufficient for class switch recombination. Critically, by comparing IgM-positive cells from clones that contained switched cells with IgM-positive cells from entirely unswitched clones, the team found no transcriptional differences between the two groups. Belonging to a clonal lineage in which a sister cell has already switched therefore confers no increased predisposition to switch, providing direct experimental support for mathematical models proposing that class switching is a stochastic, cell-intrinsic event.

Together, these findings sketch a model in which each individual B cell is governed by a unique combination of competing gene programs that regulate cell state, clonal gene expression and isotype switching, maximizing the diversity of the immune response. Memory B cells carry an intrinsic bias toward plasma cell differentiation, driven by sustained IRF4 activity, yet they retain the latent capacity to adopt a germinal center fate when PRDM1 is suppressed, a discovery that could open new strategies for directing memory cells toward antibody refinement. Naive B cells, meanwhile, hedge their bets, with stochastic IRF4 dynamics splitting their progeny between immediate antibody secretion and the germinal center where future memory is made. As the authors note, gene regulatory network inference from single-cell transcriptomics remains inherently correlative, and future work with genome-wide transcription factor binding assays and high-throughput CRISPR screens will be needed to map the causal wiring in full. Even so, the study provides the most detailed picture yet of how human B cells decide their destinies, knowledge that is directly relevant to understanding responses to infection, vaccination and autoimmunity.

Subject of Research: Gene regulatory network dynamics controlling human naive and memory B cell differentiation and fate decisions

Article Title: Competing gene regulatory networks drive naive and memory B cell differentiation

Article References: Competing gene regulatory networks drive naive and memory B cell differentiation. (n.d.). https://doi.org/10.1038/s44320-026-00207-8

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00207-8

Keywords: B cells, gene regulatory networks, plasma cells, germinal center, IRF4, PRDM1, single-cell RNA sequencing, CRISPR, class switch recombination, clonal tracking, immune memory, transcription factors

A research team led by Javier M. Di Noia at the Institut de Recherches Cliniques de Montréal, working with colleagues including François Robert and Nicole J. Francis, set out to find what distinguishes the handful of genomic regions that AID actually mutates from the thousands it merely visits. Their search converged on two proteins with a storied history in cancer biology: MLLT1, also known as ENL, and its close relative MLLT3, also known as AF9. Both are components of the super elongation complex, a molecular machine that helps RNA polymerase II push through genes during transcription. Crucially, both proteins carry YEATS domains, which are so-called histone readers, modules that recognize and bind specific chemical tags on histone proteins, the spools around which DNA is wound. This ability to read chromatin marks positions MLLT1 and MLLT3 at active, acetylated regions of the genome, including enhancers and super-enhancers.

The team’s first and most striking finding came from removing these proteins. When they deleted both MLLT1 and MLLT3 from mouse B cells, every AID-dependent mutagenic process ground to a halt. Class-switch recombination, the process that lets antibodies change their effector function, was abolished. Somatic hypermutation, which introduces point mutations into antibody variable regions to sharpen their binding, disappeared entirely. In functional terms, the double-knockout cells looked as if AID itself had been deleted, even though the enzyme was still present and expressed at normal levels. Single knockouts produced partial defects, revealing that the two proteins act redundantly, with MLLT1 playing the dominant role in mice. The effect was not limited to engineered cell lines: conditional knockout mice lacking MLLT1 or MLLT3 in their B cells showed impaired antibody class switching, and chemical inhibitors targeting the YEATS domains of both proteins suppressed immunoglobulin diversification in both mouse and human B cells.

A critical clue came from mapping where MLLT1 and MLLT3 sit in the genome. Using chromatin immunoprecipitation sequencing with spike-in normalization, the researchers found that the genomic regions that AID mutates, in both mouse and human B cells, are precisely marked by unusually high occupancy of both proteins, a signature the authors denote MLLT1/MLLT3-high. This was not a loose correlation. When the team ranked genes by MLLT1 or MLLT3 signal and stratified them at an inflection point separating high from moderate occupancy, AID targets clustered overwhelmingly in the high-occupancy group. The pattern held across B cell lines, primary mouse B cells, and human lymphoma cell lines, and it extended to the super-enhancers that aberrant somatic hypermutation frequently strikes in diffuse large B cell lymphoma. The most frequently mutated loci in a catalogue of 610 lymphoma cases correlated with MLLT1 and MLLT3 enrichment, linking the mechanism directly to human disease.

One obvious explanation for the loss of AID activity in the knockout cells would be that MLLT1 and MLLT3 are simply needed to transcribe the target genes, and without them the antibody loci fall silent. The researchers tested this rigorously and found it was not the case. Transcriptional changes after deleting both readers were modest. Measurements of nascent transcription by TT-seq, along with analyses of RNA polymerase II pausing and elongation indices, showed that the antibody germline transcripts and AID’s own expression were largely preserved. The dramatic collapse in mutagenesis could not be accounted for by changes in how much or how fast the relevant genes were being transcribed. Whatever MLLT1 and MLLT3 were doing for AID, it was something beyond their canonical role in transcriptional elongation.

The mechanistic picture that emerged is one of local concentration rather than global recruitment. The researchers showed that MLLT1 and MLLT3 are dispensable for tethering AID to chromatin in general; even without them, AID still associates broadly with the genome. What the readers provide is local enrichment: they concentrate AID specifically in the regions just downstream of promoters, within roughly two kilobases of the transcription start site, which is exactly the window in which somatic hypermutation operates. Both proteins physically bind to AID, and chromatin immunoprecipitation of tagged AID revealed that its signal at target regions drops sharply in cells lacking both readers. In other words, AID can touch the genome anywhere, but only where MLLT1 and MLLT3 pile up does it reach the concentrations needed to inflict mutations.

The most conceptually adventurous part of the study concerns how MLLT1 achieves this concentration. Beyond its structured YEATS domain, MLLT1 carries a large intrinsically disordered region, a floppy protein segment that lacks a fixed three-dimensional shape. Such regions are hallmarks of proteins that drive phase separation, the process by which certain molecules coalesce into droplet-like condensates, concentrating specific partners much like oil droplets form in water. The team purified MLLT1 and MLLT3 proteins and showed in vitro that MLLT1 forms droplets that are sensitive to the aliphatic alcohol 1,6-hexanediol and to high salt, treatments that disrupt many condensates. When they incubated these droplets with extracts from cells expressing fluorescently tagged AID, AID preferentially partitioned into the MLLT1 condensates. Live-cell imaging and partition-coefficient measurements in cells reinforced the same conclusion: AID is drawn into MLLT1-rich condensates, and this depends on AID’s own interaction surface, since a point mutation in AID, R174E, reduced its partitioning and altered its protein-proximity network as measured by BioID proximity labeling.

The functional tests were decisive. Swapping the intrinsically disordered regions between MLLT1 and MLLT3 showed that MLLT1’s disordered region is what gives it its dominant role in promoting condensates that concentrate AID in mice. Most strikingly, when the researchers artificially fused AID directly to MLLT1 or to MLLT3, forcing the enzyme into proximity with the readers regardless of natural interactions, class-switch recombination and mutagenesis were restored in cells lacking both endogenous proteins. This rescue experiment demonstrates that spatial confinement with MLLT1 or MLLT3 is not merely correlated with AID activity but is sufficient to license it, arguing that the local concentration of AID is the rate-limiting ingredient for mutagenesis at any given locus.

The implications ripple outward in several directions. For basic immunology, the work solves a long-standing puzzle by proposing a licensing model: transcription opens the door, but MLLT1/MLLT3-high chromatin determines which rooms AID is allowed to enter and vandalize. For cancer biology, it offers a mechanistic explanation for why lymphomas repeatedly acquire aberrant mutations at super-enhancers, which are precisely the structures richest in super elongation complex components and their histone-reading modules. Intriguingly, MLLT1 and MLLT3 are themselves established oncogenic players, most famously as fusion partners of MLL in acute leukemia, and small-molecule chemical probes against their YEATS domains already exist. The study raises the possibility that such inhibitors, which suppressed antibody diversification in the current experiments, could in principle modulate AID’s off-target mutagenesis in disease contexts. At the same time, the findings suggest a caution: any therapy that disrupts these condensates might impair the antibody diversification that vaccines and immune memory depend on. What began as a question about a single mutagenic enzyme has ended up connecting antibody immunity, transcriptional condensates, and lymphoma genetics into one coherent physical model, and it is likely to keep both immunologists and cancer biologists busy for years to come.

Subject of Research: Mechanism of locus-specific targeting of the mutagenic enzyme AID by the histone readers MLLT1 and MLLT3 in B cells

Article Title: Histone readers MLLT1 and MLLT3 concentrate AID to confer locus specificity

Article References: Seija, N., Gannon, S., Häfner, K. A., Gemeinhardt, T. M., Ridani, J., Alvarez, D., Provencher, M., Subramani, P. G., Poitras, C., Piskor, E.-M., Möröy, T., Vonniessen, N., Mazer, B., Navarrette, M. A., Francis, N. J., Robert, F., & Di Noia, J. M. (2026). Histone readers MLLT1 and MLLT3 concentrate AID to confer locus specificity. Nature. https://doi.org/10.1038/s41586-026-11087-1

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11087-1

Keywords: AID, MLLT1, MLLT3, somatic hypermutation, class-switch recombination, histone readers, super elongation complex, phase separation, condensates, B cell lymphoma, immunoglobulin genes, chromatin

The central message of the review is that Tfh cells are not a monolithic population. Instead, they display profound heterogeneity along two major axes: spatial distribution and phenotypic characteristics. Spatially, researchers now distinguish germinal center-resident Tfh cells, follicular mantle Tfh cells, circulating Tfh cells found in the bloodstream, and peripheral Tfh cells that populate inflamed tissues and tertiary lymphoid structures. Phenotypically, Tfh cells can be further subdivided into Tfh1, Tfh2, and Tfh17 subsets, each defined by distinct cytokine profiles and transcription factor dependencies. This layered diversity allows the immune system to tailor antibody responses to vastly different challenges, from acute viral infections to parasitic worms, but it also creates multiple points at which regulation can fail and pathology can emerge.

At the heart of Tfh cell differentiation lies a transcriptional tug-of-war between two master regulators: B-cell lymphoma 6, or Bcl-6, and cellular musculoaponeurotic fibrosarcoma oncogene homolog, better known as c-Maf. Bcl-6 is the lineage-defining factor that drives nascent CD4 T cells toward the follicular helper fate, enabling them to upregulate the chemokine receptor CXCR5, which guides their migration into B cell follicles, and to suppress alternative differentiation programs. Bcl-6 and its antagonist Blimp-1 form a reciprocal regulatory circuit: high Bcl-6 and low Blimp-1 favor Tfh commitment, whereas the opposite pattern pushes cells toward other effector fates. c-Maf, induced downstream of the costimulatory receptor ICOS, cooperates with Bcl-6 to promote expression of interleukin-21, the signature cytokine through which Tfh cells deliver help to B cells. Together, these factors orchestrate a gene expression program that is both robust and exquisitely sensitive to environmental cues.

That sensitivity is embodied by the cytokine milieu encountered during T cell priming. Interleukin-6, signaling through STAT1 and STAT3, promotes early Bcl-6 induction and Tfh differentiation, while interleukin-12 and type I interferons steer cells toward Tfh1-like phenotypes characterized by the transcription factor T-bet. Conversely, interleukin-2 acts as a brake: high IL-2 signaling through the mTORC1 pathway antagonizes Tfh differentiation, which is why IL-6-mediated suppression of IL-2 responsiveness is required for germinal center Tfh cells to emerge. Interleukin-4 and the transcription factors GATA3, Batf, and STAT6 define the Tfh2 compartment, whereas transforming growth factor-beta, acting through c-Maf and STAT3-STAT4 cooperation, can promote human Tfh differentiation and specify Tfh versus Th17 fates. Additional players such as Ascl2, Tox2, and the chromatin organizer SATB1 fine-tune chromatin accessibility and gene expression, while the kinase mTORC1 and extracellular matrix protein 1 further modulate the process.

The spatial dimension of Tfh biology has emerged as a particularly active research frontier. Landmark studies using intravital microscopy revealed that germinal center Tfh cells are highly motile, dynamically interacting with B cells in a competitive process that shapes antibody affinity maturation. Development of both germinal center B cells and Tfh cells initiates in the interfollicular zone, where antigen-presenting dendritic cells first license naive T cells before they migrate into follicles. Within germinal centers themselves, progressively differentiated Tfh subsets have been described, and recent work has identified physiologically distinct CXCR5-high, PD-1-high resident populations. Long-lived memory Tfh cells, which persist after infection or vaccination and retain remarkable plasticity, sustain humoral immunity for years, and memory-like Tfh subsets have been identified as precursors of effector Tfh cells during recall responses. Circulating CXCR5-positive CD4 T cells in human blood mirror these lymphoid tissue counterparts and contain subsets that differentially support antibody secretion, providing a convenient window into systemic humoral immunity.

The clinical significance of this heterogeneity becomes stark when Tfh subsets go awry. In viral infections, Tfh1 cells dominated by T-bet and STAT4 are critical for generating neutralizing antibodies against influenza, HIV, and SARS-CoV-2, and circulating Tfh responses in recovered COVID-19 patients have been correlated with durable antibody titers. Yet in autoimmune diseases, the very same differentiation programs can become pathological. In systemic lupus erythematosus, aberrant expansion of multiple Tfh subsets, including IL-17-producing and IL-4-producing populations, drives autoantibody production and nephritis, while T peripheral helper cells, a closely related CXCR5-negative population sharing the transcription factor c-Maf, promote B cell activation through MAF and IL-21. In rheumatoid arthritis, pathologically expanded peripheral T helper cells drive B cell responses in inflamed synovium, and STAT3 hyperactivation associates with disease activity. IgG4-related disease has been linked to CCR4-positive Tfh2 cells producing interleukin-4, and food allergy involves Tfh-derived programs that promote anaphylactic IgE, including a distinct Tfh13 subset stabilized by JunB.

Cancer adds yet another layer of complexity, because Tfh cells can play contradictory roles depending on context. Within tertiary lymphoid structures, the ectopic lymphoid aggregates that form inside tumors, Tfh cells collaborate with B cells to generate anti-tumor antibody-producing plasma cells, and neoantigen-driven collaboration between B cells and CD4 Tfh cells promotes cytotoxic CD8 T cell responses. Th1-oriented Tfh cells infiltrating breast cancer correlate with effective adaptive immunity, and microbiota-specific Tfh cells drive tertiary lymphoid structures and anti-tumor immunity in colorectal cancer. However, pro-tumor Tfh2 cells in pancreatic cancer induce detrimental IgG4 production, elevated IgG4 in melanoma patients is associated with disease progression, and regulatory T cells within tumor-associated tertiary lymphoid structures can suppress anti-tumor responses. VISTA-positive follicular regulatory T cells have been implicated in immune escape in ovarian cancer, making the Tfh-Tfr axis a potential target for combination immunotherapy.

Counterbalancing the helper activity of Tfh cells is a dedicated regulatory population: the T follicular regulatory cell, or Tfr cell. These Foxp3-positive and Bcl-6-positive cells suppress germinal center reactions, restrain cytokine production by Tfh cells, and optimize the quality of IgG responses. Tfr cells can be antigen-specific, derive from naive T cells, and even share clonal relationships with Tfh cells, with human Tfh clones shown to seed the germinal center-resident regulatory pool. Their stability and progressive differentiation are controlled by Tfh programs themselves. Mechanistically, Tfr cells deploy CTLA-4, PD-1, interleukin-10, and the neurotrophic factor neuritin to modulate B cell and T cell function, while the IL-2-mTORC1 axis and the transcription factors Bach2 and NFAT2 govern their development. Restoring the Tfr-to-Tfh balance has shown therapeutic promise in lupus nephritis models and in low-dose IL-2 trials for active SLE, and Tfr cells have been shown to restrain kidney allograft rejection by suppressing alloreactive B cells.

The translational implications of this work are already visible. The CD40 ligand antagonist dazodalibep has shown efficacy in a phase 2 trial for Sjogren’s disease, small molecules such as niclosamide and artesunate suppress Tfh expansion through STAT3 and JAK2-STAT3 pathways in lupus models, and OX40L-JAG1 cotreatment has restored follicular regulatory-helper balance in mice. As the Beijing Normal University team argues, integrating the multiple Tfh subsets into a unified systematic framework provides a new perspective for understanding humoral immune regulation and for developing targeted therapies that selectively boost protective antibody responses during infection and vaccination while dampening the pathological helper activity that fuels autoimmunity, allergy, and certain cancers. In an era when mRNA vaccines, checkpoint inhibitors, and CAR-T therapies all depend on or interact with the humoral arm of immunity, deciphering the rules that govern Tfh subset differentiation may prove to be one of immunology’s most consequential endeavors.

Subject of Research: Regulation of follicular helper T cell subset differentiation in humoral immunity, infection, autoimmunity, and cancer

Article Title: Regulation of follicular helper T cell subset differentiation in health and disease

Article References: Xin, Q., Zhao, L., Zhang, J., Liu, X., & Liu, G. (2026). Regulation of follicular helper T cell subset differentiation in health and disease. Journal of Molecular Medicine, 104(1), Article 115. https://doi.org/10.1007/s00109-026-02721-6

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02721-6

Keywords: T follicular helper cells, germinal centers, Bcl-6, c-Maf, B cell help, antibody responses, autoimmunity, systemic lupus erythematosus, T follicular regulatory cells, tertiary lymphoid structures, cancer immunology, viral infection